skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Refinado por: assunto: Middle Aged remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer

Hortobagyi, Gabriel N. ; Stemmer, Salomon M. ; Burris, Howard A. ; Yap, Yoon-Sim ; Sonke, Gabe S. ; Hart, Lowell ; Campone, Mario ; Petrakova, Katarina ; Winer, Eric P. ; Janni, Wolfgang ; Conte, Pierfranco ; Cameron, David A. ; André, Fabrice ; Arteaga, Carlos L. ; Zarate, Juan P. ; Chakravartty, Arunava ; Taran, Tetiana ; Le Gac, Fabienne ; Serra, Paolo ; O’Shaughnessy, Joyce

The New England journal of medicine, 2022-03, Vol.386 (10), p.942-950 [Periódico revisado por pares]

United States: Massachusetts Medical Society

Texto completo disponível

Citações Citado por
2
Pretreatment Serum Anti-Müllerian Hormone Predicts Long-Term Ovarian Function and Bone Mass after Chemotherapy for Early Breast Cancer
Pretreatment Serum Anti-Müllerian Hormone Predicts Long-Term Ovarian Function and Bone Mass after Chemotherapy for Early Breast Cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Pretreatment Serum Anti-Müllerian Hormone Predicts Long-Term Ovarian Function and Bone Mass after Chemotherapy for Early Breast Cancer

Anderson, Richard A ; Cameron, David A

The journal of clinical endocrinology and metabolism, 2011-05, Vol.96 (5), p.1336-1343 [Periódico revisado por pares]

Bethesda, MD: Endocrine Society

Texto completo disponível

Citações Citado por
3
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

Cameron, David, Prof ; Piccart-Gebhart, Martine J, PhD ; Gelber, Richard D, PhD ; Procter, Marion, PhD ; Goldhirsch, Aron, MD ; de Azambuja, Evandro, MD ; Castro, Gilberto, MD ; Untch, Michael, MD ; Smith, Ian, MD ; Gianni, Luca, MD ; Baselga, Jose, MD ; Al-Sakaff, Nedal, PhD ; Lauer, Sabine, PhD ; McFadden, Eleanor, MA ; Leyland-Jones, Brian, MBBS ; Bell, Richard, MBBS ; Dowsett, Mitch, PhD ; Jackisch, Christian, MD

The Lancet (British edition), 2017-03, Vol.389 (10075), p.1195-1205 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
4
Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer
Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer

Anderson, Richard A ; Rosendahl, Mikkel ; Kelsey, Thomas W ; Cameron, David A

European journal of cancer (1990), 2013-11, Vol.49 (16), p.3404-3411 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
5
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Material Type:
Artigo 		Adicionar ao Meu Espaço

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Cortazar, Patricia, Dr ; Zhang, Lijun, PhD ; Untch, Michael, Prof ; Mehta, Keyur, MBA ; Costantino, Joseph P, DrPH ; Wolmark, Norman, MD ; Bonnefoi, Hervé, Prof ; Cameron, David, Prof ; Gianni, Luca, Prof ; Valagussa, Pinuccia, BS ; Swain, Sandra M, MD ; Prowell, Tatiana, MD ; Loibl, Sibylle, Prof ; Wickerham, D Lawrence, MD ; Bogaerts, Jan, PhD ; Baselga, Jose, Prof ; Perou, Charles, PhD ; Blumenthal, Gideon, MD ; Blohmer, Jens, Prof ; Mamounas, Eleftherios P, MD ; Bergh, Jonas, Prof ; Semiglazov, Vladimir, Prof ; Justice, Robert, MD ; Eidtmann, Holger, MD ; Paik, Soonmyung, MD ; Piccart, Martine, Prof ; Sridhara, Rajeshwari, PhD ; Fasching, Peter A, Prof ; Slaets, Leen, PhD ; Tang, Shenghui, PhD ; Gerber, Bernd, Prof ; Geyer, Charles E, MD ; Pazdur, Richard, MD ; Ditsch, Nina, MD ; Rastogi, Priya, MD ; Eiermann, Wolfgang, Prof ; von Minckwitz, Gunter, Prof

The Lancet (British edition), 2014-07, Vol.384 (9938), p.164-172 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
6
Phase III Multicenter Clinical Trial of the Sialyl‐TN (STn)‐Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer
Phase III Multicenter Clinical Trial of the Sialyl‐TN (STn)‐Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase III Multicenter Clinical Trial of the Sialyl‐TN (STn)‐Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer

Miles, David ; Roché, Henri ; Martin, Miguel ; Perren, Timothy J. ; Cameron, David A. ; Glaspy, John ; Dodwell, David ; Parker, Joanne ; Mayordomo, José ; Tres, Alejandro ; Murray, James Lee ; Ibrahim, Nuhad K.

The oncologist (Dayton, Ohio), 2011-08, Vol.16 (8), p.1092-1100 [Periódico revisado por pares]

Durham, NC, USA: AlphaMed Press

Texto completo disponível

Citações Citado por
7
Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)
Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)

DE AZAMBUJA, Evandro ; PROCTER, Marion J ; JACKISCH, Christian ; CAMERON, David A ; BELL, Richard ; LEYLAND-JONES, Brian ; DOWSETT, Mitch ; GELBER, Richard D ; PICCART-GEBHART, Martine J ; SUTER, Thomas M ; VAN VELDHUISEN, Dirk J ; AGBOR-TARH, Dominique ; METZGER, Otto ; STEINSEIFER, Jutta ; UNTCH, Michael ; SMITH, Ian E ; GIANNI, Luca ; BASELGA, Jose

Journal of clinical oncology, 2014-07, Vol.32 (20), p.2159-2165 [Periódico revisado por pares]

Alexandria, VA: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
8
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial

Coleman, Robert, Prof ; Cameron, David, Prof ; Dodwell, David, FRCR ; Bell, Richard, Prof ; Wilson, Caroline, MRCP ; Rathbone, Emma, MRCP ; Keane, Maccon, MD ; Gil, Miguel, MD ; Burkinshaw, Roger, BSc ; Grieve, Robert, Prof ; Barrett-Lee, Peter, Prof ; Ritchie, Diana, FRCR ; Liversedge, Victoria, BSc ; Hinsley, Samantha, MSc ; Marshall, Helen, MSc

The lancet oncology, 2014-08, Vol.15 (9), p.997-1006 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
9
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial

Earl, Helena M, Dr ; Hiller, Louise, PhD ; Dunn, Janet A, Prof ; Blenkinsop, Clare ; Grybowicz, Louise, BSc ; Vallier, Anne-Laure, MSc ; Abraham, Jean, MBBS ; Thomas, Jeremy, MBBS ; Provenzano, Elena, MD ; Hughes-Davies, Luke, MBBCh ; Gounaris, Ioannis, MD ; McAdam, Karen, MBBS ; Chan, Stephen, MBBCh ; Ahmad, Rizvana, MBBS ; Hickish, Tamas, MBBS ; Houston, Stephen, MBBS ; Rea, Daniel, PhD ; Bartlett, John, Prof ; Caldas, Carlos, Prof ; Cameron, David A, Prof ; Hayward, Larry, MBChB

The lancet oncology, 2015-06, Vol.16 (6), p.656-666 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
10
Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group
Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

PARIDAENS, Robert J ; DIRIX, Luc Y ; BEEX, Louk V ; NOOIJ, Marianne ; CAMERON, David A ; CUFER, Tanja ; PICCART, Martine J ; BOGAERTS, Jan ; THERASSE, Patrick

Journal of clinical oncology, 2008-10, Vol.26 (30), p.4883-4890 [Periódico revisado por pares]

Baltimore, MD: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (842)

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (885)
  2. Anais de Congresso  (1)
  3. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de1986  (20)
  2. 1986Até1995  (36)
  3. 1996Até2004  (118)
  4. 2005Até2014  (325)
  5. Após 2014  (387)
  6. Mais opções open sub menu

Idioma 

  1. Japonês  (150)
  2. Norueguês  (4)
  3. Português  (2)
  4. Russo  (1)
  5. Francês  (1)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.